RedHill BioPharma $RDHL announced that it has begun a Phase 2 clinical trial assessing YELIVA (ABC294640) in patients with advanced hepatocellular carcinoma (HCC). The study will be conducted at the Medical University of South Carolina Hollings Center, including several clinical centers in the U.S. It is supported by a $1.8mn grant from the National Cancer Institute. Enrollment for the study would commence soon. The trial will evaluate YELIVA as second-line monotherapy in up to 39 participants with advanced HCC who have experienced tumor progression following treatment with first line single agent sorafenib (Bayer�s Nexavar).